Top ▲
Target not currently curated in GtoImmuPdb
Target id: 2091
Nomenclature: mitogen-activated protein kinase 4
Abbreviated Name: ERK4
Family: ERK subfamily
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 587 | 18q21.1-q21.2 | MAPK4 | mitogen-activated protein kinase 4 | |
Mouse | - | 583 | 18 E2 | Mapk4 | mitogen-activated protein kinase 4 | |
Rat | - | 274 | 18q12.2 | Mapk4 | mitogen-activated protein kinase 4 |
Previous and Unofficial Names ![]() |
MAP kinase 4 | MNK2 | p63Mapk | PRKM4 |
Database Links ![]() |
|
Alphafold | P31152 (Hs), Q6P5G0 (Mm), Q63454 (Rn) |
BRENDA | 2.7.11.24 |
ChEMBL Target | CHEMBL5759 (Hs) |
Ensembl Gene | ENSG00000141639 (Hs), ENSMUSG00000024558 (Mm), ENSRNOG00000015401 (Rn) |
Entrez Gene | 5596 (Hs), 225724 (Mm), 54268 (Rn) |
Human Protein Atlas | ENSG00000141639 (Hs) |
KEGG Enzyme | 2.7.11.24 |
KEGG Gene | hsa:5596 (Hs), mmu:225724 (Mm), rno:54268 (Rn) |
OMIM | 176949 (Hs) |
Pharos | P31152 (Hs) |
RefSeq Nucleotide | NM_002747 (Hs), NM_172632 (Mm), NM_019319 (Rn) |
RefSeq Protein | NP_002738 (Hs), NP_766220 (Mm), NP_062192 (Rn) |
UniProtKB | P31152 (Hs), Q6P5G0 (Mm), Q63454 (Rn) |
Wikipedia | MAPK4 (Hs) |
Enzyme Reaction ![]() |
||||
|
DiscoveRx KINOMEscan® screen ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1-2 |
![]() ![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: ERK4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
ERK subfamily: mitogen-activated protein kinase 4. Last modified on 19/01/2015. Accessed on 19/02/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2091.